PR Newswire Clinical TrialsOriginal article
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Data ReadoutDabogratinibNeutral
AI Analysis
Summary
Tyra Biosciences announced it will host a conference call on September 9, 2026 to discuss initial results from the SURF302 Phase 2 study of oral dabogratinib for intermediate-risk non-muscle invasive bladder cancer.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Initial results from SURF302 Phase 2 study
Importance:6/10
Sentiment:
0.00
FGFRprecision medicinebladder cancerconference callPhase 2 data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 4, 2026 12:00 PM